Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486954 | 0.79 | SMN1; SMN2 (0.51) | P2RX4BCHEMAPTKDM4ETP53 | |
| SCHEMBL2904169 | 0.78 | ALDH1A1 (0.33) | MEN1KMT2ANPSR1TP53 | |
| SCHEMBL1867242 | 0.70 | NPC1 (0.62) | MAPTCACNA1GCACNA1HCACNA1IMEN1 | |
| SCHEMBL8163089 | 0.68 | ITGB1 (0.56) | P2RX4HRH3MAPTKDM4EMEN1 | |
| SCHEMBL4865168 | 0.68 | TP53 (0.71) | MAPTTP53 | |
| SCHEMBL4235379 | 0.67 | P2RX4 (0.66) | P2RX4BCHEMAPTKDM4ECACNA1G | |
| SCHEMBL27749322 | 0.67 | KDM4E (0.45) | P2RX4BCHEHRH3KDM4EMEN1 | |
| SCHEMBL4197501 | 0.65 | KDM4E (0.69) | HRH3KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL5800630 | 0.65 | KDM4E (0.69) | HRH3KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL31202624 | 0.65 | CYP1A2 (0.42) | HRH3MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | P2RX4 4689/4885BCHE 1853/4885HRH3 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.